Chronic sildenafil in men with diabetes and erectile dysfunction

Expert Opinion on Drug Metabolism and Toxicology

Volumn 3, Issue 3, 2007, Pages 451-464

  Aversa, Antonio ^a   Bruzziches, Roberto ^a   Vitale, Cristiana ^b   Marazzi, Giuseppe ^b   Francomano, Davide ^a   Barbaro, Giuseppe ^a   Spera, Giovanni ^a   Rosano, Giuseppe M C ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Diabetes; Endothelial dysfunction; Erectile dysfunction; Phosphodiesterase type 5; Rehabilitation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERYTHROMYCIN; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROTEIN KINASE C; RIFAMPICIN; RITONAVIR; SEX HORMONE BINDING GLOBULIN; SILDENAFIL; TADALAFIL; TESTOSTERONE; UNINDEXED DRUG; VARDENAFIL; VASOACTIVE AGENT;

ARTERY BLOOD FLOW; ARTERY DIAMETER; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLOR VISION DEFECT; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; GASTROESOPHAGEAL REFLUX; GRAPEFRUIT JUICE; HEADACHE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPOTENSION; INHIBITION KINETICS; LOW DRUG DOSE; MALE; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PENIS ARTERY; PENIS ERECTION; PHOTOALLERGY; PRIAPISM; PROTEIN DEGRADATION; PSYCHOLOGICAL ASPECT; RHABDOMYOLYSIS; RISK ASSESSMENT; SEXUAL BEHAVIOR; SIDE EFFECT; SMOOTH MUSCLE FIBER; SMOOTH MUSCLE RELAXATION; TREATMENT OUTCOME; VISUAL DISORDER;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; DIABETES COMPLICATIONS; ENDOTHELIUM, VASCULAR; HUMANS; IMPOTENCE; MALE; MODELS, BIOLOGICAL; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES;

EID: 34548250417     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.3.3.451     Document Type: Article

References (130)

1. LEWIS RW, FUGL-MEYER KS, BOSCH R et al.: Definitions, Classification and epidemiology of Sexual Dysfunction. In: Sexual Medicine, Sexual dysfunctions in men and women. Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F (Eds) Plymbridge Distributors Ltd, Plymouth, UK (2004):37-72.
2. AVERSA A, PILI M, FABBRI A, SPERA E, SPERA G: Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition. J. Endocrinol. Invest. (2004) 27:192-206.
3. KANNEL WB, MCGEE DL: Diabetes and cardiovascular disease: the Framingham Study. JAMA (1979) 241:2035-2038.
4. HAFFNER SM, LEHTO S, RONNEMAA T, PYORALA K, LAAKSO M: Mortality from coronary heart disease in subjects with Type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. (1998) 339:229-234.
5. GRUNDY SM, BENJAMIN IJ, BURKE GL et al.: Diabetes and cardiovascular disease: a statement for health professionals from the American Heart Association. Circulation (1999) 100:1134-1146.
6. CUMMINGS MH: Erectile dysfunction in diabetes mellitus. In: International Textbook of Diabetes Mellitus, vol. II. DeFronzo RA, Ferrannini E, Keen H, Zimmer P (Eds), John Wiley & Sons Ltd., West Sussex, UK (2004):1333-1342.
7. BULTRINI A, CAROSA E, COLPI EM et al.: Possible correlation between Type 1 diabetes mellitus and female sexual dysfunction: case report and literature review. J. Sex Med. (2004) 1(3):337-340.
8. SAIRAM K, KULINSKAYA E, BOUSTEAD GB, HANBURY DC, MCNICOLAS TA: Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int. (2001) 88:68-71.
9. BACON CG, HU FB, GIOVANNUCCI E, GLASSER DB, MITTLEMAN MA, RIMM EB: Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care (2002) 25(8):1458-1463.
10. FEDELE D, BORTOLOTTI A, COSCELLI C et al.: Erectile dysfunction in Type 1 and Type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erectile nei Diabetici. Int. J. Epidemiol. (2000) 29(3):524-531.
11. PANZA JA, QUYYUMI AA, BRUSH JE, EPSTEIN SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. (1990) 323:22-27.
12. SCHACHINGER V, BRITTEN MB, ZEIHER AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation (2000) 101:1899.
13. VITALE C, MERCURO G, CORNOLDI A, FTNI M, VOLTERRANI M, ROSANO GM: Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med. (2005) 258(3):250-256.
14. AVERSA A, GRECO E, BRUZZICHES R, PILI M, ROSANO G, SPERA G: Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int. J. Impot. Res. (2007) 18(2):200-207.
15. GOLDSTEIN I, LUE TF, PADMA-NATHAN H, ROSEN RC, STEERS WD, WICKER PA. Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med. (1998) 338:1397-1404.
16. BALLARD SA, GINGELL CJ, TANG K, TURNER LA, PRICE ME, NAYLOR AM: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. (1998) 159:2164-2171.
17. BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penfle erectile dysfunction. Int. J. Impot. Res. (1996) 8:47-52.
18. BEAVO JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. (1995) 75:725-748.
19. RENDELL MS, RAJFER J, WICKER PA, SMITH MD: Sildenafil for the treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA (1999) 281:421-426.
20. CERIELLO A, ASSALONI R, DA ROS R et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in Type 2 diabetic patients. Circulation (2005) 111(19):2518-2524.
21. BEHR-ROUSSEL D, GORNY D, MEVEL K et al.: Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur. Urol. (2005) 47(1):87-91.
22. ROSANO GM, AVERSA A, VITALE C, FABBRI A. FINI M, SPERA G: Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur. Urol. (2005) 47(2):214-220; discussion 220-222.
23. GIULIANO F: et al. Erectile dysfunction in patients with diabetes and/or hypertension. Eur. J. Int. Med. (2001) 12:240.
24. KIM N, AZADZOI KM, GOLDSTEIN I, SAENZ DE TEJADA IS: A nitric oxide like factor mediates nonadrenergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J. Clin. Invest. (1991) 88:112-118.
25. BIVALACQUA TJ, BURNETT AL, HELLSTROM WJ, CHAMPION HC: Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity- influence of in vivo gene therapy of anti-arginase. Am. J. Physiol. Heart Circ. Physiol. (2007) 292(3):H1340-H1351.
26. BIVALACQUA TJ, HELLSTROM WJG, KADOWITZ PJ, CHAMPION HC: Increased expression of arginase 11 in human diabetic corpus cavernousm: in diabetic associated erectile dysfunction. Biochem. Biophys. Res. Commun. (2001) 283:923-927.
27. BURNETT AL: Nitric oxide in the penis: physiology and pathology. J. Urol. (1997) 157:320-334.
28. JIAAN D B, SEFTEL A D, FOGARTY J et al. Age-related increase in an advanced glycation end product in penile tissue. World J. Urol. (1995) 13:369-375.
29. SAENZ DE TEJADA I, GOLDSTEIN I, AZADZOI K, KRANE RJ, COHEN RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N. Engl. J. Med. (1989) 320(16):1025-1030.
30. PICKARD RS, KING P, ZAR MA, POWELL PH: Corpus cavernosal relaxation in impotent men. Br. J. Urol. (1994) 74(4):485-491.
31. KNISPEL HH, GOESSL C, BECKMANN R: Effects of papaverine and prostaglandin E1 on corpus cavernosum smooth muscle of arteriogenically and diabetically impotent men. Eur. Urol. (1994) 26(1):35-39.
32. SULLIVAN ME, BELL CR, DASHWOOD MR et al.: Autoradiographic localization of nitric oxide synthase binding sites in normal and diabetic rat corpus cavernosum. Eur. Urol. (1996) 30(4):506-511.
33. SULLIVAN ME, DASHWOOD MR, THOMPSON CS, MUDDLE JR. MIKHAILIDIS DP, MORGAN RJ: Alterations in endothelin B receptor sites in cavernosal tissue of diabetic rabbits: potential relevance to the pathogenesis of erectile dysfunction. J. Urol. (1997) 158(5):1966-1972.
34. FRANCAVILLA S, PROPERZI G, BELLINI C, MARINO G, FERRI C, SANTUCCI A: Endothelin-1 in diabetic and non-diabetic men with erectile dysfunction. J Urol. (1997) 158:1770-1774.
35. MORANO S, GATTI A, MANDOSI E et al. Circulating monocyte oxidative activity is increased in patients with Type 2 diabetes and erectile dysfunction. J. Urol. (2007) 177(2):655-659.
36. MCMILLAN DE: Development of vascular complications in diabetes. Vasc. Med. (1997) 2(2):132-142.
37. MORELAND RB, HUANG Y, GOLDSTEIN I et al. Inhibition of TGF-1-induced collagen synthesis in human corpus cavernosum smooth muscle by cAMP. Int. J. Impot. Res. (1996) 8:102 (Abstract 14).
38. AVERSA A, BASCIANI S, VISCA P et al.: Platelet-derived growth-factor (PDGF) and PDGF-receptors in rat corpus cavernosum: changes in expression after transient in vivo hypoxia. J. Endocrinol. (2001) 170:395-402.
39. WANG CJ, SHEN SY, WU CC, CHIANG CP: Penile blood flow study in diabetic impotence. Urol. Int. (1993) 50:209-212.
40. AKOI I, SHIMOYAMA K, AKOI N et al.: Platelet dependent thrombin generation in patients with diabetes mellitus: effects of glycaemic control on coagulability in diabetes. J. Am. Coll. Cardiol. (1996) 27:560-566.
41. CONLAN NG, FOLSOM AR, FINCH A et al.: Association of Factor VIII and Von Willebrand factor with age, race, sex and risk factors fo atherosclerosis. Thromb. Haemost. (1993) 70:380-385.
42. ITALIANO G, PETRELLI L, MARIN A et al.: Ultrastructural analysis of the cavernous and dorsal penile nerves in experimental diabetes. Int. J. Impotence Res. (1993) 5:149-160.
43. MERSDORF A, GOLDSMITH PC, DIEDERICHS N et al.: Ultrastructural changes in impotent penile tissue: a comparison of 65 patients. J. Urol. (1991) 145:749-758.
44. LINCOLN J, CROWE R, BLACKLAY PF et al.: Changes in the Vipergic, cholinergic and adrenergic innervation of human penile tissue in diabetic and non-diabetic impotent males. J Urol. (1987) 137:1053-1059.
45. WELLMER A, SHARIEF MK, KNOWLES CH et al.: Quantitative sensory and autonomic testing in male diabetic patients with erectile dysfunction. BJU Int. (1999) 83(1):66-70.
46. SHABSIGH R, RAJFER J, AVERSA A et al.: The evolving role of testosterone in the treatment of erectile dysfunction. Int. J. Clin. Pract. (2006) 60(9):1087-1092.
47. MILLS TM, REILLY CM, LEWIS RW: Androgens and penile erection: a review. J. Androl. (1996) 17:633-638.
48. CORONA G, MANNUCCI E, PETRONE L et al.: Association of hypogonadism and Type II diabetes in men attending an outpatient erectile dysfunction clinic. Int. J. Impot. Res. (2006) 18(2):190-197.
49. RHODEN EL, RIBEIRO EP, TELOKEN C, SOUTO CA: Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. BJU Int. (2005) 96(6):867-870.
50. GUAY AT: Sexual dysfunction in the diabetic patient. Int. J. Impotence Res. (2001) 13(Suppl. 5):S47-S50.
51. AVERSA A, ISIDORI AM, DE MARTINO MU et al.: Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin. Endocrinol. (2000) 53:517-522.
52. AVERSA A, ISIDORI AM, SPERA G, LENZI A, FABBRI A: Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin. Endocrinol. (2003) 58:632-638.
53. ZHANG XH, FILIPPI S, MORELLI A et al.: Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J. Sex Med. (2006) 3:253-266.
54. WATKINS SE, WILLIAMS P, RYDER KE, BONSHIER W. Psychometric assessment of diabetic impotence. Br. J. Psyhiatry (1993) 162:840-842.
55. LIN C-S, XIN ZC, LIN G, LUE TF: Phosphodiesterases as therapeutic targets. Urology (2003) 61:685-691.
56. BISCHOFF E: Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int. J. Impot. Res. (2004) 16(Suppl. 1):S11 -S4.
57. JEON YH, HEO YS, KIM CM et al.: Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol. Life. Sci. (2005) 62(11):1198-1220.
58. LIN CS, LIN G, XIN ZC, LUE TF: Expression, distribution and regulation of phosphodiesterase 5. Curr. Pharm. Des. (2006) 12(27):3439-3457.
59. AVERSA A, BRUZZICHES R, PILI M, SPERA G: Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr. Pharm. Des. (2006) 12(27):3467-3484.
60. PADMA-NATHAN H, GIULIANO F: Oral drug therapy for erectile dysfunction. Urol. Clin. North Am. (2001) 28:321-334.
61. PADMA-NATHAN H, STECHER VJ, ORAZEM J, TSENG L-J, DERIESTHAL H: Assessment of minimum time to onset of erection after Viagra (sildenafil citrate): results of a randomized, double-blind, placebocontrolled trial. Prog. Urol. (2003) 13(3 Suppl. 2):51.
62. SEFTEL AD: Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin. Cardiol. (2004) 27(4 Suppl. 1):I14-I19.
63. SUPURAN CT, MASTROLORENZO A, BARBARO G, SCOZZAFAVA A: Phosphodiesterase 5 inhibitors - drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr. Pharm. Des. (2006) 12(27):3459-3467.
64. BARBARO G, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. (2005) 11:1805-1843.
65. DRESSER GK, SPENCE JD, BAILEY DG: Pharmacokinetic-pharmacodinamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. (2000) 38(1):41-57.
66. CARSON CC, LUE TF: Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. (2005) 96:257-280.
67. KLONER RA. HUTTER AM, EMMICK JT, MITCHELL MI, DENNE J, JACKSON G: Time course of the interaction between tadalafil and nitrates. J. Am. Coll. Cardiol. (2003) 42:1855-1860.
68. KLONER RA, BROWN M, PRISANT LM, COLLINS M; for the SILDENAFIL STUDY GROUP: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J. Hypertens. (2001) 14:70-73.
69. CASTRO MM, RIZZI E, RASCADO RR, NAGASSAKI S, BENDHACK LM, TANUS-SANTOS JE: Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur. J. Pharmacol. (2004) 498(1-3):189-194.
70. GUTIERREZ CA: Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis? Am. Fam. Physician (2001) 63(4):636-637.
71. CARSON CC: Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. Curr. Urol. Rep. (2003) 4(6):488-496.
72. DEBUSK RF, PEPINE CJ, GLASSER DB, SHPILSKY A, DERIESTHAL H, SWEENEY M: Efficacy and safety of sildenafil citratc in men with erectile dysfunction and stable coronary artery disease. Am. J. Cardiol. (2004) 93(2):147-153.
73. SUNWOO S, KIM YS, CHO BL et al.: Post-marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients. Int. J. Impot. Res. (2005) 17(1):71-75.
74. ARRUDA-OLSON AM, MAHONEY DW, NEHRA A, LECKEL M, PELLIKKA PA: Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA (2002) 287(6):719-725.
75. KLONER RA: Sex and the patient with cardiovascular risk factors: focus on sildenafil. Am. J. Med. (2000) 109(Suppl. 9A): 13S-21S.
76. KOSTIS JB, JACKSON G, ROSEN R et al.: Sexual dysfunction and cardiac risk (The Second Princeton Consensus Conference). Am. J. Cardiol. (2005) 96:313-321.
77. RASHID A. The efficacy and safety of PDE5 inhibitors. Clin. Cornerstone (2005) 7:47-56.
78. ZHANG X, FENG Q, COTE RH: Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (pde6) in retinal photoreceptors. Invest. Ophthalmol. Vis. Sci. (2005) 46:3060-3066.
79. LATIES AM, ZRENNER E: Viagra (sildenafil citrate) and ophthalmology. Prog. Res. Eye Res. (2002) 21:485-506.
80. CUNNINGHAM AV, SMITH KH: Anterior ischemic optic neuropathy associated with Viagra. J. Neuroophthalmol. (2001) 21:22-25.
81. ESCARAVAGE GK, WRIGHT JD, GIVRE SJ: Tadalafil associated with anterior ischemic optic neuropathy, Arch. Ophthalmol. (2005) 123:399-400.
82. POMERANZ HD, SMITH KH, HART WM et al.: Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology (2002) 109:584-587.
83. THE ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION: TRIAL RESEARCH GROUP: Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch. Ophthalmol. (1996) 114:1366-1374.
84. RUCKER JC, BIOUSSE V, NEWMAN NJ: Ischemic optic neuropathies. Curr. Opin. Neurol. (2004) 17:27-35.
85. FELDMAN HA, JOHANNES CB, DERBY CA et al.: Erectile dysfunction and coronary risk factors: prospective results ftom the Massachusetts male aging study. Prev. Med. (2000) 30:328-338.
86. ROUMEGUERE T, WESPES E, CARPENTIER Y et al.: Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur. Urol. (2003) 44:355-369.
87. GORKIN L, HVIDSTEN K, SOBEL RE, SIEGEL R. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int. J. Clin. Pract. (2006) 60(4):500-503.
88. BANERJEE A, LOCKE-WINTER CR. ROGERS KB et al.: Preconditioning against myocardial dysfunction after ischemia and reperfusion by an α-1 adrenergic mechanism. Circ. Res. (1993) 73:656-670.
89. SCHULTZ JE, HSU AK, GROSS GJ: Ischemic preconditioning in the intact rat heart is mediated by δ1 - but not μ- or κ-opioid receptors. Circulation (1997) 97:1282-1289.
90. TRITTO I, D'ANDREA D, ERAMO N et al.: Oxygen radicals can induce preconditioning in rabbit hearts. Circ. Res. (1997) 80:743-748.
91. WALL TM, SHEEHY R, HARTMAN JC: Role of bradykinin in myocardial preconditioning. J. Pharmacol. Exp. Ther. (1994) 270:681-689.
92. FRYER RM, HSU AK, EELLS JT, NAGASE H, GROSS GJ: Opioid-induccd second window of cardioprotection: potential role of mitochondrial KATP channels. Circ. Res. (1999) 99:846-851.
93. ZHAO TC, XI L, CHELLIAH J, LEVASSEUR JE, KUKREJA RC: Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A1 receptors: evidence from gene-knockout mice. Circulation (2000) 102:902-907.
94. ZHAO TC, KUKREJA RC: Late preconditioning elicited by activation of adenosine A3 receptor in heart: role of NFjB, iNOS and mitochondrial KATP channel. J. Mol. Cell Cardiol. (2002) 34:263-277.
95. LAUDE K, BEAUCHAMP P, THUILLEZ C, RICHARD V: Endothelial protective effects of preconditioning. Cardiovasc. Res. (2002) 55:466-473.
96. MANKAD PS, AMRANI M, ROTHERY S, SEVERS NJ, YACOUB MH: Relative susceptibility of endothelium and myocardial cells to ischaemia-reperfusion injury. Acta Physiol. Scand. (1997) 161:103-112.
97. KHARBANDA RK, PETERS M, WALTON B et al.: Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation (2001) 103:1624-1630.
98. TOMAI F, CREA F, CHIARIELO L, GIOFFRE PA. Ischemic preconditioning in humans: models, mediators, and clinical relevance. Circulation (1999) 100:559-563.
99. VARDIA A. BULUSB M, REISNERB S et al.: Effects of sildenafil citrate (Viagra®) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. Eur. Urol. (2003) 43:544-551.
100. GORI T, SICURO S, DRAGONI S, DONATI G, FORCONI S, PARKER JD: Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation (2005) 111:742-746.
101. HALCOX JP, NOUR KP, ZALOS G et al.: The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J. Am. Coll. Cardiol. (2002) 40:1232-1240.
102. KUKREJA RC, SALLOUM F, DAS A et al.: Pharmacological preconditioning with sildenaffl: basic mechanisms and clinical implications. Vascul. Pharmacol. (2005) 42:219-232.
103. DAS A, XI L, KUKREJA RC: Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J. Biol. Chem. (2005) 280:12944-12955.
104. WALLIS RM, CORBIN JD, FRANCIS SH, ELLIS P: Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. (1999) 83(5A):3C-12C.
105. KUKREJA RC, OCKAILI R, SALLOUM F, YIN C, HAWKINS J, DAS A, XI L: Cardioprotection with phosphodiesterase-5 inhibition-a novel preconditioning strategy. J. Mol. Cell Cardiol. (2004) 36(2):165-173.
106. DEVAN BD, SIERRA-MERCADO D Jr, JIMENEZ M et al.: Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol. Biochem. Behav. (2004) 79(4):691-699.
107. GAZZARUSO C, GIORDANETTI S, DE AMICI E et al.: Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated Type 2 diabetic patients. Circulation (2004) 110:1-5.
108. YAVUZGIL O, ALTAY B, ZOGHI M, GURGUN C, KAYIKCIOGLU M, KULTURSAY H: Endothelial function in patients with vasculogenic erectile dysfunction. Int. J. Cardiol. (2005) 103(1):19-26.
109. HURT KJ, MUSICKI B, PALESE MA et al.: Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc. Natl. Acad. Sci. USA (2002) 99:4061-4066.
110. EL GALLEY R, RUTLAND H, TALIC R, KEANE T, CLARK H: Long-term efficacy of sildenafil and tachyphylaxis effect. J. Urol. (2001) 166:927-931.
111. CARSON CC, BURNETT AL, LEVINE LA, NEHRA A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology (2002) 60:12-27.
112. CHRISTIANSEN E, GUIRGUIS WR, COX D, OSTERLOH IH: Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int. J. Impot. Res. (2000) 12:177-182.
113. DESOUZA C, PARULKAR A, LUMPKIN D, AKERS D, FONSECA VA: Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in Type 2 diabetes. Diabetes Care (2002) 25: 1336-1339.
114. MONTORSI F, MAGA T, STRAMBI LF et al.: Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. Urology (2000) 56:906-911.
115. LIN G, XIN ZC, LUE TF, LIN CS: Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J. Urol. (2003) 170:S15-S18.
116. MUSICKI B, CHAMPION HC, BECKER RE, LIU T, KRAMER MF, BURNETT AL: Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol. Pharmacol. (2005) 68(1):226-232.
117. AYALA JE, BRACY DP, JULIEN BM, ROTTMAN JN, FUEGER PT, WASSERMAN DH: Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes (2007) 56(4):1025-1033.
118. PEGGE NG, TWOMEY AM, VAUGHTON K, GRAVENORT MB, RAMSEY MW, PRICE DE: The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. Diabet. Med. (2006) 23:873-878.
119. KATZ SD, BALIDEMAJ K, HOMMA S, WU H, WANG J, MAYBAUM S: Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J. Am. Coll. Cardiol. (2000) 36:845-851.
120. CALLES-ESCANDON J, CIPOLLA M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. (2001) 22:36-52.
121. SOMMER F, KLOTZ T, ENGELMANN U: Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year. a randomized trial. Asian J. Androl. (2007) 9(1):134-141.
122. SHAKIR SA, WILTON LV, BOSHIER A, LAVTON D, HEELEY E: Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. Br. Med. J. (2001) 322:651-652.
123. JACKSON G: Phosphodiesterase 5 inhibition: effects on the coronary vasculature. Int. J. Clin. Pract. (2001) 55:183-188.
124. HERRMANN HC, CHANG G, KLUGHERZ BD, MAHONEY PD: Hemodynamic effects of sildenafil in men with severe coronary artery disease. N. Engl. J. Med. (2000) 342:1622-1626.
125. AVERSA A. ROSANO G, VITALE C, VOLTERRANI M, FINI M, SPERA G: Effects of chronic sildenafil therapy on endothelial function in diabetic patients. 7th Meeting of European Society for Sexual Medicine, London, 5-8 December 2004. J. Sex Med. (2004) 2(Suppl. 1):20.
126. GALIÈ N, GHOFRANI HA, TORBICKI A et al.: Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353(20):2148-2157.
127. TAKIMOTO E, CHAMPION HC, LI M et al.: Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. (2005) 11(2):214-222.
128. GHOFRANI HA, VOSWINCKEL R, REICHENBERGER F et al.: Differences in hemodynamic and oxygenation responses to three p-5 Inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. (2004) 44:1488-1496.
129. PINKNEY JH, STEHOUWER CD, COPPACK SW, YUDKIN JS: Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes (1997) 46(Suppl. 2):S9-S13.
130. JACKSON G, MONTORSI P, CHEITLIN MD: Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. Urology (2006) 68(3 Suppl.):47-60.